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In patients with Brugada syndrome (BRS), especially those
who are asymptomatic, preclinical diagnosis and risk strat-
ification are vital to the prevention of the fatal ventricular
arrhythmias. The initial optimism that a diagnosis of BRS
could be made simply on the basis of distinct electrocardio-
graphic (ECG) changes (see the following text) has been
tempered, both by a high incidence of false-positive and
false-negative cases related to “waxing” and “waning” ECG
signature (1,2) and by drug- or disease-induced ECG
abnormalities resembling those in BRS (3–5). Thus, the
need for additional diagnostic tools and strict clinical criteria
for diagnosing of BRS has become evident.
In their well documented retrospective study published
elsewhere in this issue of the Journal, Dr. Ikeda et al. (6)
have presented evidence that signal-averaged electrocardi-
ography may be useful for risk stratification of patients with
ECG evidence of BRS. In a study population of BRS
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patients (primarily male) with structurally normal hearts,
who had ECGs showing “a pattern of RBBB and ST-
segment elevation in leads V1 to V3” compared to healthy
individuals with normal ECGs, they report a sensitivity of
89%, specificity of 50%, positive predictive value of 70%,
and negative predictive value of 77% for late potentials (LP)
for risk of life-threatening events. They found no correla-
tion between LP and the magnitude of ST-segment eleva-
tion, and no correlation between LP and the HV interval in
these patients. Although neither corrected QT dispersion
(QTD) nor microvolt T-wave alternans (TWA) was corre-
lated with arrhythmogenic events, detection of LP was
considered to be a “marker of conduction abnormality,”
whereas both QTD and TWA were deemed “markers of
repolarization abnormalities.” The authors conclude that
detection of LP (but not QTD or TWA) in patients with
BRS is a “useful noninvasive technique for identifying
high-risk patients” and “may support the idea that conduc-
tion disturbance per se is arrhythmogenic.” This challenges
the prevailing opinion that early repolarization abnormali-
ties but not conduction disturbances could determine the
arrhythmogenic substrate in the BRS population.
The study by Ikeda et al. (6), however, emphasizes some
important and clinically relevant questions. In this review,
we will seek to define the clinical utility and interpretation
of noninvasive and invasive diagnostic methods in BRS.
DISCUSSION
Clinical assessment of patients with suspected or docu-
mented BRS. Patients with BRS present a great challenge,
both in establishing the diagnosis and determining the
prognosis. The only treatment presently known to be
effective against sudden cardiac death (SCD) in these
patients is the implantable defibrillator (1,7).
Patients with BRS usually present themselves in one of
two situations: 1) when a resting 12-lead ECG has shown
changes compatible with BRS, or 2) when the clinical
picture (either in terms of symptoms or family history)
suggests increased risk of SCD in the setting of a structur-
ally normal heart.
Resting ECG. The ECG marker of BRS is difficult to
describe using ordinary ECG terminology (8), but typically
there are three components: 1) elevated terminal portion of
the QRS complex (prominent J-wave); 2) non-injury-
related (“idiopathic”) elevated descending ST-segment; and
3) negative T-wave in the same right-sided precordial leads.
These peculiar ECG abnormalities of ventricular repolar-
ization are often associated with right bundle branch block
(RBBB) and normal QT interval (2,7,8). The prevalence of
the ECG marker for BRS in subjects with idiopathic
ventricular fibrillation and in healthy control subjects is the
subject of ongoing investigation (9,10).
Ikeda et al. (6) used the original description of ECG
findings in BRS (“pattern” of RBBB and ST-segment
elevation in leads V1 to V3) to characterize their patients,
but at the same time stated that none of their patients had
RBBB. Compounding the diagnostic difficulties in BRS is
the clear distinction between the presence or absence of
RBBB on the 12-lead ECG. The introduction of new ECG
terms, such as “pseudo-RBBB,” “RBBB-like,” and “RBBB-
pattern,” has been of no help. We pointed out (11,12) that
in patients with BRS, early repolarization abnormalities, but
not RBBB, are an integral part of its ECG signature. When
published ECGs from BRS patients were further scruti-
nized, it became clear that the broad terminal S-wave in
leads V5 and V6 (a hallmark of RBBB) was rarely seen and
that the QRS duration in these leads was usually normal (7).
A diagnosis of RBBB should not be made in the absence of
such an S-wave and of abnormal QRS widening in all leads.
Moreover, if RBBB is truly present in a patient with BRS,
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it becomes difficult to interpret the signal-averaged ECG,
since the usual criteria for LP cannot be applied (13) (see
the following text).
When the inclusion of RBBB as part of BRS is chal-
lenged, the J-point elevation followed by downsloping
ST-segment and negative T-wave must be explained. Sim-
ilar findings in some patients with right ventricular (RV)
dysplasia (consistent with marked difference in QRS dura-
tion in lead V1 and V6 in the absence of other classical ECG
criteria for RBBB) have been referred to as parietal intra-
ventricular conduction delay or block (14), suggesting that
the conduction disturbance is related not specifically to the
conduction system but to the myocardial tissue as a whole.
In patients with BRS, this would occur without obvious
pathologic findings; in patients with RV dysplasia, myocar-
dial cells are replaced by fatty tissue.
Interlead QTD as an index of dispersion of ventricular
repolarization is not an appropriate focus in this article. The
problems in use of this ECG parameter have been exten-
sively reviewed (15–17), and we believe that QTD is not
meaningful for independent interpretation, in general, and
is without clinical value in BRS patients, particularly.
As in the case of long-QT syndrome, a diagnosis of BRS
can be established with only a degree of certainty and must
rely on both clinical presentation and diagnostic findings.
The ECG findings described above are the cornerstones for
the diagnosis and must occur either spontaneously or
following provocative testing with sodium-blocking drugs.
Since there are false-positive findings, other possible causes
for such ECG changes must be ruled out.
Signal-averaged ECG. Detection of LP is a noninvasive
diagnostic tool that can be used to identify the presence of
slow conduction and fragmentation of electrical impulse
propagation within the ventricular myocardium. This
method is used to identify high-risk patients predisposed to
ventricular tachyarrhythmias. Its sensitivity and specificity
in the prediction of arrhythmogenic events vary dependent
on the clinical setting (18,19) and the arrhythmogenic
mechanisms that underlie disease, and are significantly
compromised in the presence of the intraventricular con-
duction defects (20).
Although Ikeda et al. (6) do not specifically address how
slow conduction in the RV, frequently described in BRS
patients, may be related to LP detected by signal-averaged
ECG, this is an issue of great interest. Normal values for
signal-averaged ECG in the presence of RBBB are not
mentioned, but only the QRS width is removed from the
definition. Their observation that the QRS width in lead V6
was normal in all patients may justify their data interpreta-
tion without reference to presence or absence of RBBB. The
statement that a normal HV interval in all their patients is
evidence against the presence of RBBB is not valid. Right
bundle branch block does not usually affect the HV interval,
since the earliest ventricular activation is via the left bundle
branch. It has been demonstrated, however, that RBBB
shortens the root-mean-square voltage of the terminal
40 ms in the filtered QRS complex (RMS40) and prolongs
the duration of low amplitude signals ,40 mV in the
terminal filtered QRS complex (LAS40) (20). To our
knowledge, there are no data available regarding criteria for
an abnormal signal-averaged ECG in the setting of RBBB
and it would therefore be particularly difficult to apply
signal-average electrocardiography to patients with RBBB
who are considered to have BRS.
Programmed electrical stimulation and sodium channel
blockade. Sodium channel blocking drugs have been used
to unmask ECG changes in concealed forms of BRS (21).
Antiarrhythmic drugs like ajmaline, flecainide, propafenone
and procainamide have been shown to: 1) produce or
augment ECG changes typical of BRS, and 2) evaluate
inducibility of ventricular tachycardia/ventricular fibrillation
(VT/VF) during programmed electrical stimulation (PES)
in both apparent and concealed forms of BRS (21). Since
ajmaline is not available in the U.S., procainamide or
flecainide could be the agents of choice in this country.
In predicting patients at risk, PES has a positive predic-
tive value of 50% and a negative predictive value of 46%,
whereas the positive predictive value of pharmacologic
challenge with sodium channel blockers is 35% (22). Pro-
grammed electrical stimulation, with or without drug test-
ing, is limited by its failure to unmask most silent gene
carriers that underlie the phenotypic ST-segment elevation
in BRS. Nevertheless, electrophysiologic testing—including
provocative tests of inducibility of VT/VF and drug effects
on: 1) the magnitude of ST-segment elevation, and 2)
inducibility of VT/VF—remains the tool most appropriate
for confirmation of diagnosis and risk stratification in
patients with BRS.
In addition, an assessment of the sensitivity or specificity
of such an approach is still limited by insufficient data. In
evaluating the results of a PES, the normal ventricular
response of early repolarization and conduction in the RV
after the administration of various sodium channels blockers
must be known in order to determine the specificity and the
sensitivity of those drugs in mediating the magnitude of
ST-segment elevation and conduction velocity. Unfortu-
nately, this information is also not available presently. Since
sodium channels blockers do not normally provoke malig-
nant ventricular tachyarrhythmias, electrophysiologic test-
ing is primarily indicated for evaluating the inducibility of
VT/VF before or after drug administration.
In summary, an asymptomatic individual with drug-
induced ECG abnormalities consistent with BRS has a
good prognosis if VT/VF is not inducible during PES; an
asymptomatic individual with a spontaneously abnormal
ECG will most likely develop symptoms during follow-up,
if VT/VF is not inducible; and the patient with syncopal
episodes and an abnormal ECG is at highest risk and
requires implantable cardioverter-defibrillator (23).
Thus, as a primary electrical disease of the heart, BRS is
still not well defined, and a search for better ways to
establish the diagnosis continues. We propose that the
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presence of one major and one minor criterion from Table
1 can serve to establish a diagnosis of BRS until better and
more sensitive tests become available. Because the condi-
tions of some patients may still remain undiagnosed by such
an approach, we must work to expand the diagnostic
armamentarium and seek additional insight into the man-
agement of these patients.
Mechanisms of arrhythmia: delayed conduction versus
early repolarization abnormalities. The finding of a vari-
able degree of intraventricular conduction in patients with
BRS delay is not a surprising finding when the well-
documented genetic mutations of the sodium ion channels
are considered (24–26). While no correlation between
RBBB and SCD has yet been established in a population
other than those with BRS, the magnitude of ST-segment
elevation has been linked to the incidence of life-
threatening arrhythmic events, particularly in BRS patients
(7,11).
The reentry mechanism that underlies the arrhythmo-
genic potential in BRS has been considered based on the
high inducibility and reproducibility of VT/VF during
electrophysiologic testing (1,2). Whether development and
maintenance of re-entry are due to a delayed conduction
and/or its degree or dispersion of repolarization, however, is
not known. Moreover, it must be emphasized that all
mechanisms currently proposed to explain the arrhythmo-
genic potential of BRS are speculative and inconclusive, and
neither of the noninvasive “markers” identified by Ikeda et
al. (6) can be used to determine the full scope of arrhyth-
mogenic potential in BRS or render one hypothesis more
attractive and favorable than another.
RECOMMENDATION AND FUTURE DIRECTIONS
Because ST-T changes are seen in healthy individuals with
a good prognosis, and no (or subtle) ST-T changes are
sometimes seen in BRS patients at high risk for sudden
death, it is evident that resting ECG can never serve as an
independent tool to diagnose BRS. In the context of the
findings of Ikeda et al. (6), signal-averaged ECG would be
a reasonable next step in the diagnostic workup, and positive
detection of LP could strengthen the indication for invasive
electrophysiologic testing. Criteria defining LP are specific
for each commercial system due to differences in filters, lead
configuration and analysis algorithms (26). We favor either
an abnormal RMS40 or LAS40 (27) to define the presence of
LP in patients being evaluated for BRS. No single nonin-
vasive diagnostic method can presently establish the clinical
diagnosis of BRS, and only clinically validated invasive
electrophysiologic testing can provide risk stratification for
BRS patients. Any BRS patient with either spontaneous or
inducible ventricular tachyarrhythmias should be consider to
be at high risk for SCD and treated with an implantable
cardioverter defibrillator. Finally, the questions generated by
the study of Ikeda et al. (6) may be resolved by analysis of
follow-up data.
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